S. Leijen

发表

AML1/RUNX1 Increases During G1 to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression*

K. Ravid, Florence Bernardin-Fried, T. Kummalue, 2004, Journal of Biological Chemistry.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

A. Oza, G. Shapiro, J. Schellens, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

J. Schellens, J. Beijnen, A. Huitema, 2013, Gynecologic oncology.

A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2010 .

A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies

W. Zeng, S. Leijen, E. Woolf, 2012, Analytical and Bioanalytical Chemistry.

Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.

J. Schellens, J. Beijnen, S. Leijen, 2010, Current clinical pharmacology.

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

J. Schellens, M. Scheulen, V. Diéras, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

J. Schellens, J. Beijnen, P. Baas, 2015, Investigational New Drugs.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

D. de Jong, J. Schellens, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

J. Schellens, J. Beijnen, S. Leijen, 2013, Cancer treatment reviews.

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

J. Schellens, M. Nicolson, S. Leijen, 2011, Cancer Chemotherapy and Pharmacology.

Increased expression of the tight junction molecule claudin‐18 A1 in both experimental colitis and ulcerative colitis

C. Mulder, S. Leijen, G. Bouma, 2008, Inflammatory bowel diseases.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

D. Jong, J. Schellens, J. Beijnen, 2015 .

Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.

A. Oza, G. Shapiro, J. Schellens, 2012 .

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .